We have previously demonstrated a number of changes in the anterior lobe proopiomelanocortin (POMC) system in chronically stressed rats. The purpose of the present experiments was to investigate whether chronically stressed rats demonstrate changes in pituitary sensitivity to glucocorticoid negative feedback. To study this question we compared the effects of ghicoeorticoids on ovine corticotropin releasing factor (oCRF)-stimulated ACTH and 13-endorphin release from cell suspensions prepared from naive unhanded rats versus chronically stressed rats. After dexamethasone, there was a 50% decrease in oCRF-stimulated hormone release in control rats but no inhibition of oCRF-stimulated hormone release in anterior lobe suspension from chronically stressed rats. Rather, the chronically stressed group exhibited a 50% hormone increase above the oCRF-stimulated baseline. The same pattern was observed after the addition of corticosterone to the medium. These findings suggest that there may be a positive feedback effect of glueocorticoids at the pituitary level under some conditions of chronic stress.
INTRODUCTION
USING a chronic footshock stress model, we have demonstrated a number of changes in anterior lobe proopiomelanocortin (POMC) regulation. Following two weeks of 30 min daily footshock, there is an increase in mRNA for POMC (Shiomi et al., 1986) , a two-fold increase in POMC content (Young & Akil, 1985) , and changes in the rate of biosynthesis and of post-translational processing of POMC to its end products. We observed no evidence of a subsensitive response to oCRF challenge in short-term anterior lobe suspensions from these chronically stressed animals; in fact, there was an increased sensitivity to CRF-stimulated 13-endorphin release in anterior lobe suspensions from chronically stressed animals which were restressed prior to decapitation. Since a number of changes have been demonstrated in anterior lobe regulation of B-endorphin biosynthesis and release, it was of interest to test whether these animals demonstrated normal glucocorticoid inhibition of oCRF-stimulated hormone release from the pituitary. To evaluate Correspondence to be ~ddressed to:
Dr. Elizabeth A. Young, Mental Health Research Institute, University of Michigan, 205 Washtenaw Place, Ann Arbor M148109-0720, USA. 317 this feedback, we compared the effects of glucocorticoids on oCRF-stimulated hormone release in short-term anterior lobe suspensions from control and chronically stressed rats.
METHODS
Two groups of rats.were used. A control group consisted of animals which were unstressed and unhanded. A "chronic stress plus rest" (CS/R) group was exposed to the footshock stressor as previously described (Young & Akil, 1985) for 30 min daily for 14 days and then was allowed to rest for 24 hr. These two groups had similar plasma g-endorphin, ACTH and corticosterone concentrations at the time of decapitation. In addition, short-term anterior lobe suspensions from these animals showed the same response to oCRF (Young & Akil, 1985) .
In order to study ACq74dB-endorphin release, anterior lobe cell suspensions were prepared from these animals immediately following sacrifice. The methods for dispersing the cells and incubating them have been described previously (Young & Akil, 1985) . In brief, pituitaries were dissected into anterior and neurointermediate lobe. The anterior lobes from two animals were pooled and incubated with collagenase (3 mg/ml) in Krebs Ringer bicarbonate to dissociate the cells. The cells were washed three times and incubated in Krebs Ringer bicarbonate at 37 ° C under 95% 02:5% C02 for 90 min to stabilize the cells. The ceils were centrifuged, fresh medium was added, and aliquots of each preparation were incubated with either medium alone, dexamethasone (50 nM) alone, oCRF (0.1 nM) alone, or a combination of oCRF and dexamethasone, under 95% 02:5% C02 at 37" C. Following 60-min incubation, the medium was collected, acidified to pH 3.0, and subsequently extracted with Sep Pak Cls cartridges prior to radioimmunoassay (RIA) for 13-endorphin immunoreacfivity. For each experiment, two anterior lobes were pooled. Eight anterior lobe suspensions were studied per group.
The 13-endorphin antibody, Brenda, was used at a final dilution of 1:40,000. This antiserum recognizes 13-endorphin and 6-1ipotropin equally well when lz5I 13-endorphin is used as a radiolabeled tracer (Cahill et al., 1983) . Each sample was radioimmunoassayed for 13-endorphin three times, and the mean values were used to calculate baseline and release. Stimulated release was calculated as total 13-endorphin immunoreactivity minus baseline 6-endorphin immunoreactivity. The intra-assay variability for the 13-endorphin RIA was 7%, and the inter-assay variability ranged between 10% and 20%.
Each sample was also radioimmunoassayed for ACTH with the ACTH assay described previously (Young & Akil, 1985) . The ACTH antibody was raised against ACTH 11-24 and was used at a final dilution of 1:80,000. Synthetic human ACTH 1-39 was used as the standard and radiolabeled tracer. The intra-assay variability for the ACTH RIA was 5%, and the inter-assay variability for ACTH ranged between 10 and 30%. The ACTH and fl-endorphin data showed the same pattern, with similar percent stimulation by oCRF and similar percent suppression by dexamethasone. However, because ACTH was assayed only once, there was more variability in ACTH across samples. Therefore, we report only the B-endorphin values.
oCRF was obtained from Bachem (Torrance, CA) and was dissolved in a solution of 0.9% NaC1 with 0.1% BSA (Fraction V, Sigma) and 0.01% ascorbic acid (oCRF diluent) added. Dexamethasone sodium phosphate solution (Decadron, Merck, Sharp and Dohme) was obtained at a concentration of 24 mg/ml from the hospital pharmacy and diluted in oCRF diluent. Corticosterone was obtained from Sigma (St. Louis, MO), dissolved at a concena'ation of 2 mg/ml in 100% ethanol, and diluted in oCRF diluent to the appropriate concentration.
The effects of dexamethasone and corticosterone on oCRF-stimulated release (total release minus baseline release) were compared by two-way analysis of variance (ANOVA). Because the data were not normally distributed, all values were log transformed prior to the ANOVA.
RESULTS
In cell suspensions from control rats, with 10 -10 M oCRF as a secretagogue, an approximately two-fold increase in 6-endorphin in the medium was observed. The data are expressed as percent of unstimulated baseline. When control and chronic stress rest groups were compared, there were no differences in baseline hormone release or oCRF-stimulated release between groups. Dexamethasone had no effect on baseline (unstimulated) release in control or chronic stress cultures. Dexamethasone (50 nM) produced a 40% inhibition of oCRF-stimulated hormone release in control cell suspensions (Fig. 1) . In contrast, in cell suspensions from chronically stressed rats, dexamethasone induced a 50% increase above the The effect of dexamcthasone (50 riM) on oCRF-stimulated B-endorphin release in pituitary cell suspensions from control and chronically stressed rats (eight rats per group, two rats per suspension). Values are expressed as per cent oCRF-stimniated hormone release. There is no difference between groups in either unstimulated baseline hormone release or in oCRF stimulated release (total release minus baseline). In control cell suspensions from stressed rats, dexamethasone produced a 50% decrease in oCRF stimulated release (suppression). In contrast, dexamethasone produced an approximately 50% increase in oCRF-stimulated release in pituitary cell suspensions from chronically stressed rats (potentiation).
oCRF-stimulated baseline (Fig. 1) . There also was a significant interaction between stress and dexamethasone (F=4.54; df= 1,32; p<.04). We have found this same stimulatory effect of dexamethasone at 1 nM oCRF in pooled pituitary suspensions from chronically stressed rats. However, since we do not have data from individual animals and therefore have no estimate of variance, we cannot state that this effect is significant at the 1 nM dose of oCRF. Because dexamethasone, a synthetic steroid, has properties somewhat different from those of naturally occurring glucocorticoids, including a preference for type II glucocorticoid receptors and a lack of binding to corticosteroid binding globulin (CBG) (De Kloet & McEwen, 1976) , we next examined the effect of corticosterone, the predominant naturally occurring glucocorticoid in rats, on oCRF-stimulated l]-endorphin release in cell suspensions from control and chronically stressed animals (Fig. 2) . The dose of corticosterone was 0.2 Ixg/ml: or 0.5 ~tM. In this experiment, the same hormone release pattern occurred: In control cell suspensions, corticosterone inhibited oCRF-stimulated hormone release by about 60%, whereas it stimulated release in cell suspensions from chronically stressed rats. There again was a significant steroidstress interaction (F = 5.82, df= 1.58, p < .02). 
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FIG. 2:
Comparison of the effect of dexamethasone (50 nM) and corticosterone (500 nM) on CRF-stimulated Bendorphin release in anterior pituitary suspensions from control or chronically stressed rats. Because the steroids affected only stimulated release and not basal secretion, steroid effects are expressed as percent of CRF-stimulated hormone release for each cell suspension. In control anterior pituitary suspensions from unstressed rats, both dexamethasone and corticosterone produced a 50% decrease in CRF-stimulated hormone release (suppression). In contrast, dexamethasone and corticosterone produced an increase in CRF-stimulated release in anterior pituitary cell suspensions from chronically stressed rats (42% increase for dexamethasone, 55% increase for cordcosterone). Pituitary cells from chronically stressed rats showed a significantly different response to steroids compared to the response of cells from normal rats.
DISCUSSION
The hypothalamo-pituitary adrenal cortical (HPA) axis was long regarded as showing little adaptation to chronic stress. However newer evidence no longer supports this view, particularly for the pituitary. The pituitary content of ACTH and B-endorphin increases dramatically with adrenalectomy (Bimberg et al., 1983) and chronic footshock (Young & Akil, 1985) . The increased hormone content with chronic footshock does not appear to be accompanied by decreased sensitivity to oCRF; in fact, there appears to be an increase in sensitivity to this releasing factor in animals which are restressed before decapitation. The current data suggest that these animals have abnormal glucocorticoid feedback at the anterior pituitary. Because we did not test other doses of dexamethasone or corticosterone, it is possible that higher doses of steroids would have demonstrated normal suppression of B-endorphin in the anterior lobe suspensions from chronically stressed rats. However, the doses used in this study achieved tissue concentrations similar to those in studies demonstrating positive feedback in man (Fehm et al., 1977; 1979; Carey, 1980; Can" et al., 1984) .
Two possible explanations to account for the changes in hormone release in anterior lobe suspensions from chronically stressed rats are: an increase in CRF receptor number and/or a decrease in glucocorticoid receptor number. The identical response to oCRF stimulation in control and chronic stress/rest anterior lobe suspensions ( Fig. 1 ; Young & Akil, 1985) suggests that changes in CRF receptor number would not explain the increased response to oCRF plus glucocorticoids in these suspensions. Previous reports of increased CRF stimulation, adrenalectomy (Wynn et al., 1985) , and chronic stress (Hauger et al., 1986) have indicated decreases in CRF receptors rather than increases. The evidence for pituitary glucocorticoid receptor down-regulation is also unclear.
Pituitary steroid receptor numbers have been shown to increase in vivo after adrenalectomy and to decrease in vitro in cultures continuously exposed to corticosteroids in the medium (Svec & Rudis, 1981) . Demonstration of pituitary steroid receptor down-regulation in vivo has been more difficult. Using a number of daily stressors as well as daily injections with corticosterone in a long acting preparation, Sapolsky et al. (1984) have shown a decrease in steroid receptor numbers in several brain regions, but no changes in the number of pituitary steroid receptors. Certainly, the footshock-endured increase in corticosterone in this stress paradigm is of a smaller magnitude than that of the chronic corticosterone injection paradigm.
However, a change in steroid receptor number is not necessary to explain our finding. Nor is it clear that these effects are mediated by the classic glucocorticoid receptor. Schwartz et al. (1986) have shown that glucocorticoids appear to bind directly to the CRF receptor, and Childs et al. (1986) have shown that glucocorticoids can directly affect CRF receptor number. It is quite possible that the effects of either antagonism or potentiation of CRF-stimulated hormone release in vitro are mediated through a non-glucocorticoid receptor mechanism. The potentiation of oCRF-stimulated hormone release can be explained by a positive feedback mechanism in the pituitary for glucocorticoids. Such positive feedback effects of glucocorticoids have been reported in patients with Cushing's disease and severe depression (James et al., 1965; Krieger et al., 1975; Fehm et al., 1977; 1979; Carey, 1980; Carr et al., 1984) . In other systems, such as the gonadal steroid system, positive feedback effects of sex steroid hormones have been noted (Yamaji et al., 1971; Nakai et al., 1978) . Likewise, the effects of glucocorticoids are not always the same at different levels of the HPA axis. Mahmoud et al. (1984) reported that l l-deoxycorticosterone or l l-deoxycortisol can antagonize the negative feedback effect of corticosterone fast feedback in intact rats, while these same steroids show negative feedback effects on pituitary ACTH release in vitro in delayed feedback paradigms and in fast feedback studies on brain-lesioned rats. Thus, there is some indication that the positive or negative coupling of different steroids may vary across levels of the HPA axis as well as across experimental conditions and feedback paradigms. If such a change in coupling occurs to elicit positive feedback at the pituitary, then one would not necessarily expect a decrease in steroid receptor number, because such a decrease would lead to a blunted negative feedback response rather than a positive response. Finally, it is possible that a decrease in the classic glucocorticoid inhibitory response leads to an uncovering of an already existing stimulatory effect of glucocorticoids. Our data do not allow us to distinguish between this hypothesis and a "switch" hypothesis. In either case, glucocorticoids can have stimulatory effects at the pituitary. The lack of effect of glucocorticoids alone (in the absence of oCRF) in this experimental paradigm suggests that this stimulatory effect is not a simple one but requires an interaction with oCRF.
We conclude that daily phasic stimulation of the HPA axis can uncover a positive feedback effect of glucocorticoids on the pituitary. This stimulatory effect of steroids on the pituitary provides a possible explanation for our previously reported paradoxical response to an acute stress in anterior lobe cell suspensions from chronically stressed rats (Young & Akil, 1985) . These studies provide in vitro evidence of a proposed positive feedback loop occurring in Cushing's patients and in some patients with endogenous depression (James et al., 1965; Krieger et al., 1975; Fehm et al., 1977; 1979; Carey, 1980; Carr et al., 1984) . It is unclear whether this change results from a change in the coupling of the receptor to a second messenger system or from a different and unknown mechanism. Although such changes may seem counter-intuitive in a chronically driven system, they may enable the organism to meet continually the demands imposed by repeated chronic stress without the risk of steroid negative feedback exerting too great a clamp on the system. In addition, they may be coupled to counterbalancing feedback influences at the suprapituitary level, permitting the system to adapt to recurring demands with a different set of regulatory mechanisms. The physiological or environmental events which would foster such mechanisms in vivo need to be explored.
